Sphera Funds Management LTD. raised its position in CytomX Therapeutics (NASDAQ:CTMX) by 12.5% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 180,000 shares of the biotechnology company’s stock after acquiring an additional 20,000 shares during the period. Sphera Funds Management LTD. owned approximately 0.46% of CytomX Therapeutics worth $5,121,000 as of its most recent filing with the SEC.
A number of other institutional investors have also recently made changes to their positions in CTMX. Wells Fargo & Company MN grew its stake in CytomX Therapeutics by 47.3% in the third quarter. Wells Fargo & Company MN now owns 60,739 shares of the biotechnology company’s stock valued at $1,104,000 after acquiring an additional 19,506 shares during the period. Bank of Montreal Can purchased a new position in shares of CytomX Therapeutics during the fourth quarter valued at approximately $124,000. Schwab Charles Investment Management Inc. boosted its position in shares of CytomX Therapeutics by 4.9% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 176,502 shares of the biotechnology company’s stock valued at $3,726,000 after buying an additional 8,279 shares during the last quarter. First Quadrant L P CA boosted its position in shares of CytomX Therapeutics by 122.6% during the fourth quarter. First Quadrant L P CA now owns 18,948 shares of the biotechnology company’s stock valued at $400,000 after buying an additional 10,437 shares during the last quarter. Finally, Algert Global LLC boosted its position in shares of CytomX Therapeutics by 11.7% during the fourth quarter. Algert Global LLC now owns 51,233 shares of the biotechnology company’s stock valued at $1,082,000 after buying an additional 5,380 shares during the last quarter. 75.97% of the stock is owned by hedge funds and other institutional investors.
CytomX Therapeutics opened at $25.74 on Thursday, MarketBeat Ratings reports. CytomX Therapeutics has a 1-year low of $13.00 and a 1-year high of $35.00. The firm has a market capitalization of $985.23 million, a price-to-earnings ratio of -22.19 and a beta of 0.95.
CytomX Therapeutics (NASDAQ:CTMX) last posted its quarterly earnings data on Wednesday, March 7th. The biotechnology company reported $0.02 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.43) by $0.45. CytomX Therapeutics had a negative return on equity of 92.68% and a negative net margin of 67.88%. The business had revenue of $27.07 million for the quarter, compared to analysts’ expectations of $10.70 million. equities analysts expect that CytomX Therapeutics will post -1.47 EPS for the current year.
In other CytomX Therapeutics news, insider Rachel Humphrey sold 23,840 shares of the business’s stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $30.00, for a total value of $715,200.00. Following the transaction, the insider now owns 54,074 shares of the company’s stock, valued at $1,622,220. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Sean A. Mccarthy sold 19,578 shares of the business’s stock in a transaction on Tuesday, May 1st. The stock was sold at an average price of $26.55, for a total value of $519,795.90. Following the completion of the transaction, the chief executive officer now directly owns 24,221 shares in the company, valued at approximately $643,067.55. The disclosure for this sale can be found here. In the last three months, insiders sold 123,578 shares of company stock worth $3,633,036. Insiders own 8.50% of the company’s stock.
Several brokerages recently issued reports on CTMX. Cantor Fitzgerald set a $40.00 target price on CytomX Therapeutics and gave the company a “buy” rating in a research report on Wednesday, May 9th. Cowen reaffirmed a “buy” rating on shares of CytomX Therapeutics in a research report on Thursday, May 10th. BidaskClub cut CytomX Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, May 11th. Zacks Investment Research cut CytomX Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, January 24th. Finally, ValuEngine raised CytomX Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, April 2nd. Five equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $38.43.
CytomX Therapeutics Profile
CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 anti-cancer target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel tumor antigen; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.
Want to see what other hedge funds are holding CTMX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CytomX Therapeutics (NASDAQ:CTMX).
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.